BlackRock Japan Boosts J&J and Pfizer Share Sizes in Quarterly Filing

Wall St. Watchdog reveals information regarding BlackRock Japan Co. Ltd.’s top holdings in the Healthcare sector for the quarter ending September 30th, 2011. The firm held 246 stocks in the Healthcare sector at the end of the quarter with an aggregate market value of $2.159 billion.

  • Johnson & Johnson (NYSE:JNJ): On 06/30/2011, BlackRock Japan Co. Ltd. reported holding 3,914,329 shares with a market value of $260,381,152. This comprised 1.1% of the total portfolio. On 09/30/2011, BlackRock Japan Co. Ltd. reported holding 4,482,932 shares with a market value of $285,517,933. This comprised 1.38% of the total portfolio. The net change in shares for this position over the two quarters is 568,603. About Company: Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
  • Pfizer Inc. (NYSE:PFE): On 06/30/2011, BlackRock Japan Co. Ltd. reported holding 12,882,621 shares with a market value of $265,381,998. This comprised 1.12% of the total portfolio. On 09/30/2011, BlackRock Japan Co. Ltd. reported holding 14,864,125 shares with a market value of $262,797,735. This comprised 1.27% of the total portfolio. The net change in shares for this position over the two quarters is 1,981,504. About Company: Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company’s products include prescription pharmaceuticals, non-prescription self-medications, and animal health products such as anti-infective medicines and vaccines.
  • Merck & Co. Inc. (NYSE:MRK): On 06/30/2011, BlackRock Japan Co. Ltd. reported holding 5,546,667 shares with a market value of $195,741,884. This comprised 0.83% of the total portfolio. On 09/30/2011, BlackRock Japan Co. Ltd. reported holding 5,756,502 shares with a market value of $188,237,620. This comprised 0.91% of the total portfolio. The net change in shares for this position over the two quarters is 209,835. About Company: Merck & Co., Inc. is a global pharmaceutical company that discovers, develops, manufactures, and markets a broad range of human and animal health products. Merck’s products include a treatment for elevated cholesterol, a treatment for male pattern hair loss, a preventive treatment for osteoporosis, a treatment for hypertension, and a treatment for allergic rhinitis.
  • Abbott Laboratories (NYSE:ABT): On 06/30/2011, BlackRock Japan Co. Ltd. reported holding 2,480,959 shares with a market value of $130,548,060. This comprised 0.55% of the total portfolio. On 09/30/2011, BlackRock Japan Co. Ltd. reported holding 2,262,748 shares with a market value of $115,716,931. This comprised 0.56% of the total portfolio. The net change in shares for this position over the two quarters is -218,211. About Company: Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company’s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
  • Amgen Inc. (NASDAQ:AMGN): On 06/30/2011, BlackRock Japan Co. Ltd. reported holding 1,841,219 shares with a market value of $107,435,126. This comprised 0.45% of the total portfolio. On 09/30/2011, BlackRock Japan Co. Ltd. reported holding 1,882,741 shares with a market value of $103,475,444. This comprised 0.5% of the total portfolio. The net change in shares for this position over the two quarters is 41,522. About Company: Amgen Inc. discovers, develops, manufactures, and markets human therapeutics based on cellular and molecular biology. The Company focuses its research on secreted protein and small molecule therapeutics, with particular emphasis on neuroscience and cancer. Amgen concentrates on the areas of hematology, cancer, infectious disease, endocrinology, neurobiology, and inflammation.
  • Bristol-myers Squibb Company (NYSE:BMY): On 06/30/2011, BlackRock Japan Co. Ltd. reported holding 3,944,597 shares with a market value of $114,235,526. This comprised 0.48% of the total portfolio. On 09/30/2011, BlackRock Japan Co. Ltd. reported holding 2,483,150 shares with a market value of $77,921,245. This comprised 0.38% of the total portfolio. The net change in shares for this position over the two quarters is -1,461,447. About Company: Bristol-Myers Squibb Company is a global biopharmaceutical company that discovers, develops, manufactures and sells pharmaceutical and nutritional products. The Company’s products and experimental therapies address cancer, heart disease, HIV/AIDS, diabetes, rheumatoid arthritis, hepatitis, organ transplant rejection and psychiatric disorders.
  • Unitedhealth Group Inc. (NYSE:UNH): On 06/30/2011, BlackRock Japan Co. Ltd. reported holding 1,684,259 shares with a market value of $86,874,082. This comprised 0.37% of the total portfolio. On 09/30/2011, BlackRock Japan Co. Ltd. reported holding 1,565,845 shares with a market value of $72,216,770. This comprised 0.35% of the total portfolio. The net change in shares for this position over the two quarters is -118,414. About Company: UnitedHealth Group Incorporated owns and manages organized health systems in the United States and internationally. The Company provides employers products and resources to plan and administer employee benefit programs. UnitedHealth also serves the health needs of older Americans, provides specialized care services, and provides health care information and research to providers and payers.
  • Celgene Corporation (NASDAQ:CELG): On 06/30/2011, BlackRock Japan Co. Ltd. reported holding 867,806 shares with a market value of $52,346,058. This comprised 0.22% of the total portfolio. On 09/30/2011, BlackRock Japan Co. Ltd. reported holding 1,013,134 shares with a market value of $62,723,126. This comprised 0.3% of the total portfolio. The net change in shares for this position over the two quarters is 145,328. About Company: Celgene Corporation is a global biopharmaceutical company. The Company focuses on the discovery, development, and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
  • Eli Lilly & Co. (NYSE:LLY): On 06/30/2011, BlackRock Japan Co. Ltd. reported holding 2,136,443 shares with a market value of $80,180,703. This comprised 0.34% of the total portfolio. On 09/30/2011, BlackRock Japan Co. Ltd. reported holding 1,539,429 shares with a market value of $56,912,692. This comprised 0.27% of the total portfolio. The net change in shares for this position over the two quarters is -597,014. About Company: Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company’s products are sold in countries around the world. Eli Lilly’s products include neuroscience products, endocrine products, anti-infectives, cardiovascular agents, oncology products, and animal health products.
  • Medtronic Inc. (NYSE:MDT): On 06/30/2011, BlackRock Japan Co. Ltd. reported holding 1,521,399 shares with a market value of $58,619,502. This comprised 0.25% of the total portfolio. On 09/30/2011, BlackRock Japan Co. Ltd. reported holding 1,601,478 shares with a market value of $53,233,131. This comprised 0.26% of the total portfolio. The net change in shares for this position over the two quarters is 80,079. About Company: Medtronic, Inc. develops therapeutic and diagnostic medical products. The Company’s principal products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, heart failure management, heart valve replacement, malignant and non-malignant pain, and movement disorders. Medtronic’s products are sold worldwide.

(Note: Data regarding BlackRock Japan Co. Ltd.’s stock holdings are sourced from whalewisdom.com. All data are assumed to be accurate.)

Advantage: Check out our interactive stock charts, fundamentals, Twitter stream, and more >>

Improve Your 2011 Financial Health: Join the winning team of stock pickers with Wall St. Cheat Sheet’s acclaimed premium newsletter>>